SBSander Bins

Sander Bins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sander Bins has a total of 211 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors

    by D.C.H. van Dorst, M.M. Hofman, R.M. de Waal, E. Oomen-De Hoop, K. de Joode, S. Bins, S.L.W. Koolen, A. Joosse, J. Versmissen, M.J.H.A. Kruip, et al.


  • Open Access

    Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1

    by Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J. de Neijs, Esther Oomen - de Hoop, Esther van Meerten, Ron H. N. van Schaik, Ron H. J. Mathijssen, et al.

    Background and objective Side effects of irinotecan treatment can be dose limiting and may impair quality of life. In this study, we investigated the correlation between single nucleotide polymorphisms (SNPs) in genes encoding enzymes involved in the irinotecan metabolism and transport, outside UGT1A1, and irinotecan-related toxicity. We focused on carboxylesterases, which are involved in formation of the active metabolite SN-38 and on drug transporters. Methods Patients who provided written informed consent at the Erasmus Medical Center Cancer Institute to the Code Geno study (local protocol: MEC02-1002) or the IRI28-study (NTR-6612) were enrolled in the study and were genotyped for 15 SNPs in the genes CES1, CES2, SLCO1B1, ABCB1, ABCC2, and ABCG2. Results From 299 evaluable patients, 86 patients (28.8%) developed severe irinotecan-related toxicity. A significantly higher risk of toxicity was seen in ABCG2 c.421C>A variant allele carriers (P = 0.030, OR 1.88, 95% CI 1.06–3.34). Higher age was associated with all grade diarrhea (P = 0.041, OR 1.03, 95% CI 1.00–1.06). In addition, CES1 c.1165-41C>T and CES1 n.95346T>C variant allele carriers had a lower risk of all-grade thrombocytopenia (P = 0.024, OR 0.42, 95% CI 0.20–0.90 and P = 0.018, OR 0.23, 95% CI 0.08–0.79, respectively). Conclusion Our study indicates that ABCG2 and CES1 SNPs might be used as predictive markers for irinotecan-induced toxicity.


  • Open Access

    Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

    by Niels A. D. Guchelaar, Bo J. Noordman, Stijn L. W. Koolen, Bianca Mostert, Eva V. E. Madsen, Jacobus W. A. Burger, Alexandra R. M. Brandt-Kerkhof, Geert-Jan Creemers, Ignace H. J. T. de Hingh, Misha Luyer, et al.

    Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. Intraperitoneal chemotherapy, which is administered repeatedly into the peritoneal cavity through a peritoneal implanted port, could provide a novel treatment modality for this patient population. This review provides a systematic overview of intraperitoneal used drugs, the performed clinical studies so far, and the complications of the peritoneal implemental ports. Several anticancer drugs have been studied for intraperitoneal application, with the taxanes paclitaxel and docetaxel as the most commonly used drug. Repeated intraperitoneal chemotherapy, mostly in combination with systemic chemotherapy, has shown promising results in Phase I and Phase II studies for several tumor types, such as gastric cancer, ovarian cancer, colorectal cancer, and pancreatic cancer. Two Phase III studies for intraperitoneal chemotherapy in gastric cancer have been performed so far, but the results regarding the superiority over standard systemic chemotherapy alone, are contradictory. Pressurized intraperitoneal administration, known as PIPAC, is an alternative way of administering intraperitoneal chemotherapy, and the first prospective studies have shown a tolerable safety profile. Although intraperitoneal chemotherapy might be a standard treatment option for patients with unresectable peritoneal disease, more Phase II and Phase III studies focusing on tolerability profiles, survival rates, and quality of life are warranted in order to establish optimal treatment schedules and to establish a potential role for intraperitoneal chemotherapy in the approach to unresectable peritoneal disease.


  • Open Access

    Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD

    by Mirjam de With, Leni van Doorn, Demi C. Maasland, Tessa A.M. Mulder, Esther Oomen-De Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H.N. van Schaik, et al.


  • Open Access

    Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors

    by Wesley S. van de Geer, Ron H.J. Mathijssen, Job van Riet, Neeltje Steeghs, Mariette Labots, Carla van Herpen, Lot A. Devriese, Vivianne C.G. Tjan-Heijnen, Emile E. Voest, Stefan Sleijfer, et al.


  • Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension

    by Leni van Doorn, Wesley J. Visser, Daan C. H. van Dorst, Katrina M. Mirabito Colafella, Stijn L. W. Koolen, Anneke van Egmond- de Mik, Ingrid M. Garrelds, Dominique M. Bovée, Esther Oomen- de Hoop, Sander Bins, et al.

    Background Vascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer agents which often induce hypertension. VEGFI-induced hypertension is sodium-sensitive in animal studies. Therefore, the efficacy of dietary sodium restriction (DSR) to prevent VEGFI-induced hypertension in cancer patients was studied. Methods Cancer patients with VEGFI-induced hypertension (day mean >135/85 mmHg or a rise in systolic and/or diastolic BP ≥ 20 mmHg) were treated with DSR (aiming at P = 0.009). DSR prevented the rise in the endothelin-1/renin ratio that normally accompanies VEGFI-induced hypertension (P = 0.020) and prevented the onset of proteinuria: 0.15 (0.10–0.25) g/24 h with DSR versus 0.19 (0.11–0.32) g/24 h without DSR; P = 0.005. Discussion DSR significantly attenuated VEGFI induced BP rise and proteinuria and thus is an effective non-pharmacological intervention.


  • Open Access

    Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study

    by Edwin A. Basak, Niels S. Vermeer, Karlijn de Joode, Daan P. Hurkmans, Dorian E.M. Velthuis, Esther Oomen-De Hoop, Marco W.J. Schreurs, Sander Bins, Stijn L.W. Koolen, Reno Debets, et al.


  • DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events

    by Mirjam de With, Gemma Brufau, Laila A. van Den Berg, Femke M. de Man, Marija Trajkovic, Martine F. Thijs, Rob Castel, Henricus J. Vermeer, Samira el Bouazzaoui, Amber van Hemel, et al.

    PURPOSE: Around 20%-30% of patients treated with fluoropyrimidines develop severe treatment-related adverse events (AEs). These are mainly caused by deficiency of dihydropyrimidine dehydrogenase, its main metabolizing enzyme. The DPYD*7 variant allele contains a frameshift mutation that leads to absence of dihydropyrimidine dehydrogenase. Clinical studies on this variant in patients treated with fluoropyrimidines are lacking because of its low minor allelic frequency. However, the DPYD*7 minor allelic frequency is 56-times higher in the Dutch compared with the global population. This allowed us to evaluate fluoropyrimidine tolerability in DPYD*7 variant allele carriers. MATERIALS AND METHODS: Patients treated with standard-of-care fluoropyrimidine who were pretreatment DPYD genotyped for DPYD*2A, *13, 2846A>T, and 1236G>A single-nucleotide polymorphisms were included for analyses. Patients were additionally screened for the DPYD*7 allele (rs72549309, 295-298delTCAT). AEs were graded if they worsened from baseline, according to Common Terminology Criteria for Adverse Events version 5.0. AEs ≥ grade 3 were considered severe. RESULTS: From 3,748 patients, we found 13 patients carrying heterozygous DPYD*7. Relevant clinical data were available for 11 patients. All patients developed fluoropyrimidine-related AEs, of which five patients developed severe AEs (46%). From these five patients, three patients were started with 65% or 50% of standard dose, but apparently still developed severe toxicity. Because of severe AEs, three patients discontinued treatment prematurely (one patient already started with 50% of standard dose) and one patient who started with 50% of standard dose was further reduced to 35% of standard dose. CONCLUSION: In this study, the clinical consequences of carrying the DPYD*7 variant allele were confirmed as 46% of the patients developed severe AEs, even in the presence of initial dose reductions. This underlines the need for prospective studies investigating the required fluoropyrimidine dose for DPYD*7 carriers.


  • Open Access

    UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

    by Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit A.L.M. Deiman, Jesse J. Swen, Saskia Houterman, Stijn L.W. Koolen, Sander Bins, Anna M.J. Thijs, et al.